Focused On-demand Library for Interleukin-10 receptor subunit alpha

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q13651

UPID:
I10R1_HUMAN

ALTERNATIVE NAMES:
CDw210a; Interleukin-10 receptor subunit 1

ALTERNATIVE UPACC:
Q13651; A8K6I0; B0YJ27

BACKGROUND:
The Interleukin-10 receptor subunit alpha, known alternatively as CDw210a, is integral to the body's immune response. It mediates the effects of IL10, a cytokine critical for anti-inflammatory pathways, by forming a complex that activates intracellular kinases and STAT3. This activation leads to the suppression of excessive inflammatory responses and inhibits autophagy under starvation conditions.

THERAPEUTIC SIGNIFICANCE:
Given its central role in controlling inflammation, IL10RA represents a promising target in the treatment of Inflammatory bowel disease 28, autosomal recessive. This disease, encompassing Crohn's disease and ulcerative colitis, could benefit from therapies aimed at modulating IL10RA activity. Harnessing the anti-inflammatory capabilities of IL10RA offers a hopeful avenue for alleviating symptoms and improving quality of life for affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 206 of 8789